{"id":382423,"date":"2025-10-08T07:00:00","date_gmt":"2025-10-08T07:00:00","guid":{"rendered":"https:\/\/dailybanglanewspapers.com\/news\/bbg-advanced-therapies-and-cellforcure-partner-to-provide-transatlantic-manufacturing-solutions-for-advanced-therapy-medicinal-products-atmps\/"},"modified":"2025-10-08T07:00:00","modified_gmt":"2025-10-08T07:00:00","slug":"bbg-advanced-therapies-and-cellforcure-partner-to-provide-transatlantic-manufacturing-solutions-for-advanced-therapy-medicinal-products-atmps","status":"publish","type":"post","link":"https:\/\/dailybanglanewspapers.com\/news\/bbg-advanced-therapies-and-cellforcure-partner-to-provide-transatlantic-manufacturing-solutions-for-advanced-therapy-medicinal-products-atmps\/","title":{"rendered":"BBG Advanced Therapies and CELLforCURE Partner to Provide Transatlantic Manufacturing Solutions for Advanced Therapy Medicinal Products (ATMPs)"},"content":{"rendered":"

<\/p>\n

\n

San Antonio, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) — BBG Advanced Therapies, a subsidiary of BioBridge Global (San Antonio, Texas, USA), and CELLfor<\/i>CURE, part of SEQENS Group, (Les Ulis, France) are proud to announce a partnership dedicated to supporting the development and large-scale production of Advanced Therapy Medicinal Products (ATMPs).<\/p>\n

This collaboration establishes a transatlantic connection enabling U.S. companies to leverage CELLfor<\/i>CURE\u2019s manufacturing capabilities in Europe, while European companies can benefit from BBG Advanced Therapies\u2019 production capacities in the United States. Together, they provide enhanced global CDMO capacity and an integrated service network to support the development and manufacturing needs of ATMP developers.<\/p>\n

BBG Advanced Therapies integrates cell and tissue expertise with cutting-edge biomanufacturing capabilities, which include a strong track record in MSC-based projects as well as adherence to relevant FDA, EMA and PMDA regulations.\u00a0 Supporting innovators with progressing early-stage development through late-phase readiness and market launch, BBGAT\u2019s holistic ecosystem of services spans leukapheresis, donor management, testing, cryopreservation and assay development, all under a unified Quality Management System. \u00a0BBGAT has 9 cGMP cleanrooms spanning over 558 m2<\/sup> (6,000 sq. ft.) and a process development space spanning over 232 m2<\/sup> (2,500 sq. ft.).\u00a0 With an eye toward advancing the industry and expanding patient access, BBGAT also maintains the world\u2019s only mobile leukapheresis center.<\/p>\n

CELLfor<\/i>CURE, EMA-authorized and FDA-compliant, combines a unique blend of CDMO heritage and proven commercial manufacturing expertise from Phase I to full-scale commercial production. Its \u201cone-stop-shop\u201d facility spans 10,000 m\u00b2, including 3,000 m\u00b2 (32,291 sq. ft.) of GMP-certified areas across 7 independent manufacturing lines, each with 8 cleanrooms, ensuring maximum safety and compliance for every product.\u00a0 CELLfor<\/i>CURE has a strong track record in CAR-T manufacturing as well as immune cells therapies, standing as a trusted, comprehensive solution provider. The company enables seamless project development by leveraging in-house Quality Control for 90% of processes, ensuring high-quality drug product delivery.<\/p>\n

United by a shared vision to remove barriers in ATMPs manufacturing solutions, this collaboration creates a fully scalable, global CDMO partnership between USA and Europe that accelerates the journey from concept to commercialization. By combining transatlantic expertise and infrastructure, the partnership enables therapy developers to scale rapidly, launch multinational trials, and reach patients more effectively. Together, BBG Advanced Therapies and CELLfor<\/i>CURE now offer state-of-the-art GMP manufacturing space, providing unmatched capacity to support global clients.<\/p>\n

About BBG Advanced Therapies:<\/strong>\u00a0\u00a0BBG Advanced Therapies provides innovative and custom solutions to accelerate the development of cell and gene therapies. BBG Advanced Therapies features a fully integrated and custom portfolio of innovative solutions, including collection and processing of starting materials, testing, clinical trials support, and biomanufacturing services. BBG Advanced Therapies is a subsidiary of BioBridge Global and is\u00a0 based in San Antonio, Texas. Learn more at BBGAdvancedTherapies.org<\/strong><\/a>.<\/p>\n

About BioBridge Global:<\/strong> BioBridge Global is a 501(c)(3) nonprofit healthcare services enterprise headquartered in San Antonio, Texas, that offers diverse services through its nonprofit subsidiaries \u2013 South Texas Blood & Tissue, QualTex Laboratories, BBG Advanced Therapies and The Blood & Tissue Center Foundation.\u202fBioBridge Global provides products and services in blood resource management, cellular therapy, donated umbilical cord blood and human tissue, as well as testing of blood, plasma and tissue products for clients in the United States and worldwide.\u202f The enterprise enables advances in the field of regenerative medicine and advanced therapies by providing access to starting materials, testing services, biomanufacturing and clinical trials support.\u202f BioBridge Global is committed to saving and enhancing lives through the healing power of human cells and tissue.\u202f Learn more at BioBridgeGlobal.org<\/strong><\/a>.\u202f<\/p>\n

About CELLfor<\/i>CURE: <\/strong>CELLforCURE SAS is a CDMO authorized by ANSM (French Regulatory Authority), dedicated to ATMPs production from concept to commercialization. With advanced technologies, extensive capabilities, and large-scale capacity, CELLfor<\/i>CURE offers a seamless journey from early-stage development to commercial manufacturing of a wide range of cell therapies. CELLfor<\/i>CURE is part of SEQENS group.\u00a0 \u00a0Learn more at\u00a0cellandgene.seqens.com<\/strong><\/a>. <\/strong><\/p>\n

About SEQENS: <\/strong>SEQENS is a global partner in health, personal care and specialty ingredients. We empower innovation to bring the best solutions to our customers, with a constant concern for sustainability.\u00a0 Relying on the skills of 3300 employees, we leverage a worldwide manufacturing network of 15 manufacturing sites and 9 state-of-the-art R&D centers in 9 countries. As an end-to-end player across the value chain, SEQENS offers a broad range of active ingredients, pharmaceutical intermediates, personal care & specialty ingredients. We innovate, develop and industrialize the most demanding molecules, and implement the best available technologies. Learn more at seqens.com<\/strong><\/a>.<\/strong><\/p>\n